8-KOther EventsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Corporate Update (Apr 3, 2015)

Filed April 3, 2015For Securities:JNJ

Summary

Johnson & Johnson (JNJ) announced through its subsidiary, Janssen Pharmaceuticals, Inc., the completion of a significant divestiture on April 1, 2015. The company has sold its U.S. license rights for the NUCYNTA® (tapentadol) product line, which includes immediate-release, extended-release, and oral solution formulations, to Depomed. This strategic move generated $1.05 billion in proceeds for Johnson & Johnson, representing a substantial cash inflow that could be utilized for future investments, debt reduction, or shareholder returns. Investors should view this as a step towards portfolio optimization, allowing the company to potentially focus resources on core therapeutic areas or higher-growth opportunities. The financial impact of this sale will be reflected in future financial statements.

Key Highlights

  • 1Janssen Pharmaceuticals, a JNJ subsidiary, completed the divestiture of NUCYNTA® U.S. license rights.
  • 2The sale generated $1.05 billion in cash proceeds for Johnson & Johnson.
  • 3The divested products include NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets, and NUCYNTA® (tapentadol) oral solution.
  • 4The transaction primarily impacts the U.S. market for these specific pain management medications.
  • 5This divestiture suggests a strategic refinement of Johnson & Johnson's pharmaceutical portfolio.
  • 6The press release detailing the transaction is attached as an exhibit.
  • 7The event date for the divestiture was April 1, 2015.

Frequently Asked Questions

Johnson & Johnson, through its subsidiary Janssen Pharmaceuticals, Inc., divested the U.S. license rights to the NUCYNTA® (tapentadol) product line. This includes NUCYNTA® (tapentadol) for immediate release, NUCYNTA® ER (tapentadol) extended-release tablets, and NUCYNTA® (tapentadol) oral solution.

Johnson & Johnson received $1.05 billion from the sale of the NUCYNTA® U.S. license rights to Depomed.

This divestiture is significant as it represents a $1.05 billion cash inflow, potentially bolstering JNJ's financial flexibility for strategic investments, debt repayment, or shareholder distributions. It also indicates a focus on portfolio optimization, allowing the company to concentrate on its core and high-growth segments within the pharmaceutical sector.

Depomed acquired the U.S. license rights to the NUCYNTA® product line.